Presentation Slides
Download
Report
Transcript Presentation Slides
BioSense 2.0
Public Health Surveillance through Collaboration
Barbara L. Massoudi, MPH, PhD
BioSense Redesign Project Director,
RTI International
Any views or opinions expressed here do not necessarily represent the views of the CDC, HHS, or any other entity of the United States
government. Furthermore, the use of any product names, trade names, images, or commercial sources is for identification purposes only, and
does not imply endorsement or government sanction by the U.S. Department of Health and Human Services.
Office of Surveillance, Epidemiology, and Laboratory Services
Public Health Surveillance Program Office
History of BioSense
2002
Mandated in the Public Health Security and Bioterrorism (BT)
Preparedness and Response Act of 2002
Nationwide “integrated system” for early detection and assessment of
potential BT-related illness
2003
Funding provided by Congress to CDC
Development of BioSense infrastructure started, initial focus on:
• VA and DoD
• Direct reporting to CDC of detailed clinical data by civilian hospitals (initiated
in 2004)
2006
Began soliciting more limited data from health departments that had
already established automated systems for ED-based syndromic
surveillance
• By 2007, 8 state/local HDs connected
Epidemiologic Objectives
Syndromic Surveillance & BioSense
Early event detection
Rapid event characterization (regardless of how
detected)
Ongoing & timely monitoring over course of event
Situation Awareness Value Examples
2011
Japan Earthquake/Tsunami
Cluster of Visits for Heat-Related Illness in Texas
2010
Dengue surveillance - Florida
Gulf Oil Spill
Maryland anti-infective pharmaceutical surveillance
2009
H1N1 event and Distribute
BioSense 1.0 Environment
Jurisdiction
Hospital
Public-Access
Recommendations from Prior Evaluations
(GAO, US Senate, ASTHO, CSTE, BioSense Evaluation Project)
Strengthen state and local public health engagement
Enhance state/local HD syndromic surveillance capacity
Increase participation of state/local HD syndromic surveillance
systems (improve coverage)
Share data with HDs from hospitals reporting directly to CDC
Share governance
Leverage investments in EHRs
GAO, 2008: Adopt an “open, distributed computing
model”
Improve utility of the data and data sources
Preparedness role: Greater “all hazards” emphasis
Expand uses for broader spectrum of PH concerns
BioSense 2.0: Approach
Shift from a need-to-know to a need-to-share and co-create
“User-Centered” design
Partners engaged in every step of the redesign
Low barrier to participation for HDs and their providers
• HDs fully control “their data” at the level of granularity they are authorized
• Support expansions in SS prompted by Meaningful Use (MUse)
More options for data sharing
• HDs are able to share data directly with other jurisdictions and CDC
Alignment with ONC and MUse
Agreed upon core SS data elements (CDC/ISDS/ONC collaboration)
Enhanced partnerships
States (ELC): MUse SS adoption, building capacity, joining BioSense 2.0
Collaborations with associations (ASTHO, CSTE, NACCHO) and ISDS
Simple and unobtrusive technology option
Cloud technology; distributed, easy to adopt, cost-effective, and secure
The Cloud: A Scalable Solution
BioSense 2.0: Timeline
June-October 2011: Governance, Cloud, and Recruitment
Established an interim S&L governance structure
Identified and procured Amazon as the Cloud vendor
Recruitment in coordination with ASTHO, NACCHO, CDC, and ISDS (67 jurisdictions)
November 2011: Open for Business
S&L HDs can initiate or expand their syndromic surveillance systems under the MUse
program for their own jurisdiction
Stakeholders can begin collaborating among themselves and CDC in the new
environment governed by data use agreements
By April 2012: Retire BioSense 1.0
Followed EPLC process (internal to OSELS and the CDC enterprise)
BioSense 2.0: Environment
BioSense 2.0
Environment
Shared
Spaces
Jurisdiction
Hospital
Public-Access
BioSense 2.0: Environment
Four primary services
Catcher’s Mitt
• Provides for securely receiving (multiple channels), storing, and
processing high volumes of data for jurisdictions at no cost to them
Data Conversion
• Can receive all data forms and formats, including HL7 or CDA, and
convert them to any format an individual health department uses
Analytics
• Compatible environment for the users’ requested analytic tools, such
as: SAS and R statistical packages, ESSENCE, etc
Collaboration
• Allows for ad hoc or continual data sharing among jurisdictions based
on data use agreements initiated by the jurisdiction and signed with
ASTHO
Application Home Page
Shared Space
A “View” consists of a map, timeline and
metadata
• Save View for viewing later or sharing
• Data can be filtered by demo, sources
• Statistical anomaly detection tools
• A view can be annotated with notes that are
saved for future use and for sharing
• The View can be shared within a jurisdiction
or other BioSense users (who have similar
permissions)
• Export View as: .csv, .html, .png, .ppt, .pdf
• Self-defined alerts, based on frequency,
statistics, etc. sent to email or phone
data.biosen.se
Linux virtual machine
Apache
PHINMS
VPN Mirth
secure FTP
NwHIN (Direct Project,
Connect, etc.
credentials,
metadata
BioSense 2.0: Recruitment
Recruitment is lead by CSTE and coordinated
with ASTHO, NACCHO and ISDS
First Tier
• Jurisdictions that have explicitly communicated their interest
• 26: 16 States, 3 Counties, and 7 Cities
Second Tier
• Jurisdictions with either mature capacity or high value with
moderate interest
• 35: 29 States (including DC), 5 Counties, and 1 City
Third Tier
• Jurisdictions who haven’t expressed interest at this time
• 6: 6 States [LA, CA, NJ, TX, AL, and RI]
BioSense 2.0: Technical Assistance
Assist jurisdictions in joining the environment is part of
the redesign contract
Direct program and application TA
Challenge Grants administered by the redesign contract and
coordinated with the associations
• FY 2012: 10 jurisdictions at $20K each
Technology and science innovation prizes administered by the
redesign contract and coordinated with ISDS and academic
partners
Thank You!
BioSense 2.0
http://biosenseredesign.org
[email protected]
Any views or opinions expressed here do not necessarily represent the views of the CDC, HHS, or any other entity of the United States
government. Furthermore, the use of any product names, trade names, images, or commercial sources is for identification purposes only, and
does not imply endorsement or government sanction by the U.S. Department of Health and Human Services.